Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis
Aurinia combines a profitable, high-margin lupus nephritis franchise with underappreciated autoimmune pipeline optionality, creating an asymmetric value setup if patent defenses hold and clinical catalysts mature.
Overview
Aurinia is a cash-generating commercial-stage autoimmune biopharma built around LUPKYNIS, the first FDA-approved oral therapy for adult active lupus nephritis. Its U.S. product sales and Otsuka-led international royalties fund pipeline development without near-term dilution. LUPKYNIS is clinically differentiated by predictable pharmacokinetics, no therapeutic drug monitoring, rapid proteinuria reduction, podocyte stabilization, and broad clinical usability. The Kezar acquisition expands Aurinia beyond lupus nephritis into autoimmune hepatitis and systemic autoimmune indications through zetomipzomib and aritinercept.